EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of penicillamine and trientine in the treatment of Wilson’s disease: An analysis of the FDA Adverse Event Reporting System (FAERS) database

Wenlong Qian, Kou Xu, Shuo Li, Zhuo Zhang, Xiaoxiao Hou, Bingjie Min, Jia Ling, Xinyu Zhu, Hui Zhou, Wenjuan Xu, Wenming Yang, Shijian Cao und 1 weitere

PLOS One · 12.11.2025 · 20 (11) · e0336721

DOI: 10.1371/journal.pone.0336721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 12.11.2025. Verfasst von Wenlong Qian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Penicillamine, Hepatolenticular Degeneration, Adverse Drug Reaction Reporting Systems, Trientine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Projects of Natural Science Foundation Program for Universities in Anhui Province, Scientific Research Project on TCM Inheritance and Innovation in Anhui Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Penicillamine(D-Penicillamine) and trientine are first-line therapies for Wilson’s Disease (WD), yet real-world data on their adverse events (AEs) remain scarce. We analyzed the FDA Adverse Event Reporting System (FAERS) to comprehensively assess the safety of penicillamine and trientine in WD treatment.

Methods

AEs for penicillamine and trientine (2004Q1–2024Q4) were analyzed using Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), and Bayesian Confidence Propagation Neural Network (BCPNN).

Results

We found 1,452 and 760 AEs related to penicillamine and trientine, respectively. In all adverse event (AE) reports, the ratio of females to males was approximately 1.3, with the highest proportion of AE reports in the 21–30 age group, and the largest number of AE reports coming from the United States. Signal detection showed that the most commonly reported AEs for penicillamine and trientine were drug hypersensitivity and tremor, respectively, with the highest proportions in the SOC categories of immune system disorders and gastrointestinal disorders. The main AEs for both drugs involved condition aggravated, and identified potential safety signals requiring further validation for the two drugs, such as decreased bone density and brain atrophy for penicillamine, and memory impairment, oesophageal ulcer and starvation for trientine. In addition, we found that women were more likely to experience drug hypersensitivity in penicillamine adverse event reports, while men were more likely to experience cutis laxa.

Conclusion

This study reveals the characteristics of AEs and potential associated risks in the clinical application of penicillamine and trientine, emphasizing individualized medication and vigilant monitoring strategies to provide guidance for safe medication use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PenicillamineHepatolenticular DegenerationAdverse Drug Reaction Reporting SystemsTrientineHumansFemaleMaleUnited StatesAdultUnited States Food and Drug AdministrationYoung AdultChildAdolescentMiddle AgedDatabases, FactualChild, PreschoolChelating AgentsAged

Substanzen

PenicillamineTrientineChelating Agents

Autor:innen und Institutionen

  • Department of Neurology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, China.
  • Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine, Institute of Health and Medicine Hefei Comprehensive National Science Center, Hefei, Anhui, China.
  • Key Laboratory of Xin'An Medicine, Ministry of Education, Anhui, China.

ORCID-Profile: Yonghua Chen

Förderung

  • Key Projects of Natural Science Foundation Program for Universities in Anhui Province
  • Scientific Research Project on TCM Inheritance and Innovation in Anhui Province
  • National Natural Science Foundation of China

Zitieren

APA

Qian, W., Xu, K., Li, S., Zhang, Z., Hou, X., Min, B., Ling, J., Zhu, X., Zhou, H., Xu, W., Yang, W., Cao, S., & Chen, Y. (2025). Safety of penicillamine and trientine in the treatment of Wilson’s disease: An analysis of the FDA Adverse Event Reporting System (FAERS) database. PLOS One, 20(11), e0336721. https://doi.org/10.1371/journal.pone.0336721

Vancouver

Qian W, Xu K, Li S, Zhang Z, Hou X, Min B, et al. Safety of penicillamine and trientine in the treatment of Wilson’s disease: An analysis of the FDA Adverse Event Reporting System (FAERS) database. PLOS One. 2025;20(11):e0336721. doi:10.1371/journal.pone.0336721

BibTeX
@article{Qian2025,
  author = {Qian, Wenlong and Xu, Kou and Li, Shuo and Zhang, Zhuo and Hou, Xiaoxiao and Min, Bingjie and Ling, Jia and Zhu, Xinyu and Zhou, Hui and Xu, Wenjuan and Yang, Wenming and Cao, Shijian and Chen, Yonghua},
  title = {Safety of penicillamine and trientine in the treatment of Wilson’s disease: An analysis of the FDA Adverse Event Reporting System (FAERS) database},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {11},
  pages = {e0336721},
  doi = {10.1371/journal.pone.0336721}
}
Kostenlos starten →